Skip to main content

Table 1 Baseline demographics and comorbid conditions in EVOLVE-1, EVOLVE-2 and REGAIN studies

From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

 Placebo (N = 1451)GMB 120 mg (N = 705)GMB 240 mg (N = 730)
Demographics
 Age, mean years, (SD)41.8 (11.6)40.8 (11.5)40.4 (11.9)
 Gender (female), n (%)1237 (85.3)599 (85.0)609 (83.4)
 Race, n (%)
  White1112 (76.6)545 (77.3)a555 (76.1)
  Black or African American117 (8.1)53 (7.5)a59 (8.1)
  Asian89 (6.1)48 (6.8)a42 (5.8)
  American Indian or native Alaska24 (1.7)10 (1.4)a16 (2.2)
  Native Hawaiian or other pacific islander2 (0.1)0a4 (0.6)
  Multiple107 (7.4)49 (7.0)a53 (7.3)
 Region, n (%)
  North America977 (67.3)472 (67.0)496 (68.0)
  Europe262 (18.1)126 (17.9)131 (18.0)
  Other212 (14.6)107 (15.2)103 (14.1)
 Years since migraine diagnosis, mean (SD)21.1 (12.7)20.7 (12.5)19.6 (12.3)
Comorbid conditions that occurred in > 10% of all participants, n (%)
 Seasonal allergy307 (21.2)158 (22.4)122 (16.7)
 Drug hypersensitivity247 (17.0)123 (17.5)128 (17.5)
 Insomnia165 (11.4)89 (12.6)78 (10.7)
 Anxiety166 (11.4)82 (11.6)81 (11.1)
 Depression181 (12.5)84 (11.9)79 (10.8)
 Back pain151 (10.4)62 (8.8)75 (10.3)
  1. Abbreviations:GMB galcanezumab, ISR injection-site reaction, N number of participants in the intent-to-treat population, n number of participants within each specific category, SD standard deviation
  2. aN = 729
  3. Note: All values are for injection-site reactions during the double-blind treatment phase from study start up to 6 months for EVOLVE-1 and EVOLVE-2 and up to 3 months for REGAIN